Medtronic Inc. (NYSE:MDT) presented positive results from a study of its CoreValve aortic valve replacement device using the subclavian artery, rather than the femoral.*
Medtronic claims the CoreValve is the only transcatheter aortic valve implantation device available for subclavian access.